R-Pharm: Breast Neoplasms trials

The registry lists 15 Breast Neoplasms studies with R-Pharm as lead sponsor. 0 are open to participants now and 10 have results posted.

Phase 1 4Phase 2 8Phase 3 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast CancerTerminatedNCT00634088Phase 1Results posted
• Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast CancerCompletedNCT00633464Phase 2Results posted
• Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast CancerCompletedNCT00593827Phase 2Results posted
• A Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast CancerCompletedNCT00568022Phase 1Results posted
• Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast CancerTerminatedNCT00546364Phase 2Results posted
• A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast CancerCompletedNCT00490646Phase 2Results posted
• A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast CancerCompletedNCT00370552Phase 2Results posted
• Phase I Combination w/ EpirubicinCompletedNCT00322374Phase 1Results posted
• Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast CancerCompletedNCT00082433Phase 3Results posted
• Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast CancerCompletedNCT00080301Phase 3Results posted
• A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast CancerActive, not recruitingNCT07386938Phase 3
• A Rollover Study of Ixabepilone (BMS-247550) In Patients With Metastatic Breast Cancer Previously Treated With An AnthracyclineCompletedNCT01027208Phase 2
• Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane ResistantCompletedNCT01019577Phase 2
• Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)CompletedNCT00080262Phase 2
• BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast CancerStatus unknownNCT00049244Phase 1